These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23388565)

  • 1. Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer.
    Refaat T; Choi M; Gaber G; Kiel K; Mehta M; Gradishar W; Small W
    Am J Clin Oncol; 2014 Oct; 37(5):480-5. PubMed ID: 23388565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
    Montero AJ; Avancha K; Glück S; Lopes G
    Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
    Wu Q; Wang X; Zhang M; Liao W; Wang F; Li Q
    Oncol Res Treat; 2020; 43(4):153-159. PubMed ID: 32187596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France.
    Petitjean A; Smith-Palmer J; Valentine W; Tehard B; Roze S
    BMC Cancer; 2019 Feb; 19(1):140. PubMed ID: 30744578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
    Rodgers M; Soares M; Epstein D; Yang H; Fox D; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():1-12. PubMed ID: 21609648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium.
    van Kampen RJW; Ramaekers BLT; Lobbezoo DJA; de Boer M; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FPJ; van Riel JMG; Peters NAJB; Tjan-Heijnen VCG; Joore MA
    Eur J Cancer; 2017 Jul; 79():238-246. PubMed ID: 28245951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.
    Dedes KJ; Matter-Walstra K; Schwenkglenks M; Pestalozzi BC; Fink D; Brauchli P; Szucs TD
    Eur J Cancer; 2009 May; 45(8):1397-406. PubMed ID: 19147344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
    Delaloge S; Pérol D; Courtinard C; Brain E; Asselain B; Bachelot T; Debled M; Dieras V; Campone M; Levy C; Jacot W; Lorgis V; Veyret C; Dalenc F; Ferrero JM; Uwer L; Kerbrat P; Goncalves A; Mouret-Reynier MA; Petit T; Jouannaud C; Vanlemmens L; Chenuc G; Guesmia T; Robain M; Cailliot C
    Ann Oncol; 2016 Sep; 27(9):1725-32. PubMed ID: 27436849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.
    Goulart B; Ramsey S
    Value Health; 2011; 14(6):836-45. PubMed ID: 21914503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
    Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
    Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
    Kovic B; Xie F
    J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
    Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.
    Wang X; Huang C; Li M; Gu Y; Cui Y; Li Y
    Tumour Biol; 2014 May; 35(5):4841-8. PubMed ID: 24570182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
    Weng X; Huang X; Li H; Lin S; Rao X; Guo X; Huang P
    Am J Clin Oncol; 2020 May; 43(5):340-348. PubMed ID: 32028340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
    Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
    Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
    Miles D; Cameron D; Bondarenko I; Manzyuk L; Alcedo JC; Lopez RI; Im SA; Canon JL; Shparyk Y; Yardley DA; Masuda N; Ro J; Denduluri N; Hubeaux S; Quah C; Bais C; O'Shaughnessy J
    Eur J Cancer; 2017 Jan; 70():146-155. PubMed ID: 27817944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.
    Fabi A; Russillo M; Ferretti G; Metro G; Nisticò C; Papaldo P; De Vita F; D'Auria G; Vidiri A; Giannarelli D; Cognetti F
    BMC Cancer; 2012 Oct; 12():482. PubMed ID: 23083011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
    Rui M; Shi F; Shang Y; Meng R; Li H
    Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.
    Minion LE; Bai J; Monk BJ; Robin Keller L; Ramez EN; Forde GK; Chan JK; Tewari KS
    Gynecol Oncol; 2015 Jun; 137(3):490-6. PubMed ID: 25766118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.